Inactive Instrument

Press Releases IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	Apr. 02	PR
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	Mar. 27	PR
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	Mar. 20	AQ
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	Mar. 19	PR
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	Mar. 12	PR
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech and Services Conference	Mar. 08	AQ
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference	Mar. 07	PR
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024	Mar. 04	PR
Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging and Interventions Workshop	Feb. 28	AQ
Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer	Feb. 27	AQ
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop	Feb. 27	PR
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer	Feb. 26	PR
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan	Feb. 15	PR
U.S. FDA Grants IceCure Medical's Appeal, Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer	Jan. 31	AQ
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class	Jan. 30	AQ
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer	Jan. 30	PR
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation	Jan. 16	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Press Releases

Filters